Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This early proof-of-concept clinical data marks an exciting milestone for Mirati |
| So we believe actually that the targeted approach with the long tail of an IO combination will be very attractive to the market |
| And we are quite confident that we will be able to see that this progression-free survival continues to maintain |
| We are very excited about the future of Mirati and the potential to make a significant impact in the fight against cancer |
| In conclusion, KRAZATI is well positioned to become the market-leading product in a growing KRAS G12C market |
| There is also a meaningful opportunity to better identify patients with a KRAS G12C mutation, at the local account level in the electronic medical record system |
| I am confident in the strength of our team and the wealth of experience we possess |
| Looking ahead, we believe that significant opportunity remains to grow our market share in the second-line setting by increasing the depth of our prescriber base, and increasing depth of use and expanding the addressable market |
| We have a robust pipeline and innovative programs with one of the most productive drug discovery organizations in the industry |
| Additionally, data showing KRAZATI's activity in patients, with central nervous system metastasis has been favorably received by physicians |
| Additionally, our patient services have been well received, with patients able to obtain drug in an average of only four days of an oncologist's prescription, which is significantly ahead of analogs closer to two weeks |
| In second-line non-small cell lung cancer, Ben will describe how the differentiated profile of KRAZATI, along with the world-class commercial organization, have led to a strong initial launch and the promise of continued growth |
| I am very optimistic and very excited about the future of Mirati |
| We are well positioned to create significant value for shareholders while also making a meaningful impact on the lives of people living with cancer |
| From a reimbursement, access and coverage perspective, we are pleased with our rapid progress as our access and medical teams have achieved broad unrestricted coverage, with minimal access barriers for patients |
| The differentiated efficacy profile has resonated well with health care providers and patients alike |
| Our product launch continues to gain momentum and we witnessed robust demand for KRAZATI, as we generated $13.4 million of net product revenue in the second quarter |
| On slide 12, the efficacy outcomes for the adagrasib plus pembrolizumab combination in TPS greater than 50% are highly encouraging and comfortably see the outcomes of pembrolizumab monotherapy, which is the standard of care for these patients |
| The commercial performance and execution were very strong and we are thrilled with the positive impact we are making reaching more patients in need of treatment |
| I'm delighted to share the very strong results we achieved during our second full quarter since the launch of KRAZATI |
| The Phase I/II study continues to enroll well with strong interest from both patients and investigators |
| The 70-fold selectivity and pharmaceutical properties of 1719 also support its potential as both a first-in-class and best-in-class opportunity |
| Safety has also been encouraging |
| Under David's guidance the past two years, we have continued to advance our robust R&D pipeline and made a lasting impact on people living with cancer |
| The combination of adagrasib with cetuximab has shown a compelling and differentiated profile in third-line or later colorectal cancer, and we are on track to submit the supplemental new drug application for accelerated approval in the fourth quarter of this year |
| The emerging preliminary PK results are favorable with a long half-life supporting QD administration and roughly proportional increases in exposure within the therapeutic range |
| However, safety and tolerability profile of the adagrasib plus pembrolizumab combination continues to be favorable, which will potentially enable us to add adagrasib to the KEYNOTE-189 regimen |
| These data also highlight a significant opportunity to introduce a novel and meaningful therapeutic approach to the significant population of patients with MTAP-deleted cancers in need of new treatment options |
| So we are overall very encouraged by the overall safety profile of dose intensity |
| Overall, we are pleased with the significant progress we've made across our portfolio |
| Statement |
|---|
| Additionally, the Kaplan-Meier curve on the right indicates that patients with tumors harboring an MTAP deletion have a significantly poor prognosis compared to those without an MTAP gene deletion across a composite of major solid tumors |
| However, we believe that a negative opinion could be based on the fact that there is an existing conditionally approved KRAS inhibitor |
| This generally resulted in a narrow therapeutic index, dose-limiting hematologic toxicities and low single-digit response rates due to incomplete target coverage |
| Treatment-related adverse events led to treatment discontinuation of either adagrasib or pembrolizumab in 18% of patients and both drugs in just 4% of patients |
| Notably, only two patients or 1.4% discontinued the combination due to liver treatment-related adverse events |
| In addition, there was results from a competitor, which showed potentially underwhelming pivotal results, which we believe could be -- could have been part of the extrapolation there |
| We saw two Grade 2 intolerable adverse events of vomiting and fatigue |
| I wanted to just ask about -- there was a slide that mentioned liver-related adverse events that led to discontinuations that looked pretty low |
| The most common adverse events have been fatigue, nausea and diarrhea |
| We have some experience at the lower doses for a number of scans |
| Importantly, most of these adverse events were low grade and manageable, which led to acceptably low rates of dose reduction and dose interruption of either adagrasib or pembrolizumab |
Please consider a small donation if you think this website provides you with relevant information